The stock of Athersys, Inc. (NASDAQ:ATHX) is a huge mover today! About 291,577 shares traded hands. Athersys, Inc. (NASDAQ:ATHX) has risen 17.42% since March 3, 2016 and is uptrending. It has outperformed by 9.07% the S&P500.
The move comes after 5 months positive chart setup for the $188.01 million company. It was reported on Oct, 6 by Barchart.com. We have $4.75 PT which if reached, will make NASDAQ:ATHX worth $223.73 million more.
Analysts await Athersys, Inc. (NASDAQ:ATHX) to report earnings on November, 3. They expect $-0.11 earnings per share, down 37.50% or $0.03 from last year’s $-0.08 per share. After $-0.08 actual earnings per share reported by Athersys, Inc. for the previous quarter, Wall Street now forecasts 37.50% negative EPS growth.
According to Zacks Investment Research, “Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company’s lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived “off the shelf” stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications.”
Insitutional Activity: The institutional sentiment decreased to 2.14 in 2016 Q2. Its down 0.32, from 2.46 in 2016Q1. The ratio is negative, as 12 funds sold all Athersys, Inc. shares owned while 10 reduced positions. 23 funds bought stakes while 24 increased positions. They now own 14.56 million shares or 52.63% more from 9.54 million shares in 2016Q1.
Hightower Advsr Lc holds 0% or 39,100 shares in its portfolio. California Public Employees Retirement has 174,000 shares for 0% of their US portfolio. Legal General Group Public Limited Liability Com has 13,939 shares for 0% of their US portfolio. The New Jersey-based Sabby Llc has invested 0.01% in Athersys, Inc. (NASDAQ:ATHX). Catawba Management Va holds 0.01% of its portfolio in Athersys, Inc. (NASDAQ:ATHX) for 10,000 shares. Moreover, Royal Natl Bank Of Canada has 0% invested in Athersys, Inc. (NASDAQ:ATHX) for 2,082 shares. Raymond James Fin Advisors has invested 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX). State Street last reported 0% of its portfolio in the stock. Wells Fargo Mn, a California-based fund reported 32,885 shares. Jacobs Levy Equity Mgmt holds 0.01% of its portfolio in Athersys, Inc. (NASDAQ:ATHX) for 187,354 shares. Private Advisor Group Ltd Liability accumulated 14,168 shares or 0% of the stock. Vanguard Group holds 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX) for 3.22M shares. Manufacturers Life Insurance Commerce The accumulated 56,392 shares or 0% of the stock. Northern has 266,384 shares for 0% of their US portfolio. Nationwide Fund Advisors accumulated 0% or 47,940 shares.
Insider Transactions: Since September 15, 2016, the stock had 0 insider buys, and 2 sales for $35,323 net activity. Lehmann William JR also sold $5,874 worth of Athersys, Inc. (NASDAQ:ATHX) shares. Shares for $29,449 were sold by Harrington John J.
ATHX Company Profile
Athersys, Inc., incorporated on June 7, 2005, is an international biotechnology firm that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. The Company’s activities consist primarily of research and product development activities. The Company’s clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. MultiStem treatment enhances tissue repair and healing in multiple ways, including reducing inflammatory damage, protecting tissue that is at risk following acute or ischemic injury, and promoting formation of new blood vessels in regions of ischemic injury. These cells appear to be responsive to the environment in which they are administered, by homing to sites of injury and/or organs involved in injury response, and providing active disease response, while producing proteins that may provide benefit in both acute and chronic conditions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.